FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563842059> ?p ?o ?g. }

• W2563842059 abstract "Background: Various vasopressor agents are used for the treatment of cardiovascular shock. According to a randomized double-blind comparison study reported in 2010, norepinephrine is more useful than dopamine for patients in cardiovascular shock. In Japan, although both norepinephrine and dopamine are used as first-line vasopressor agents, the status of use and usefulness of the two agents have not yet been clarified. Methods: The Japanese Circulation Society (JCS) Shock Registry was a prospective, observational, multi-center, cohort study between May 2012 and June 2014.Of the patients registered in the JCS-Shock Registry, data of those who received norepinephrine or dopamine as a vasopressor agent, without the use of intra-aortic ballon pumping or cardiopulmonary bypass, were examined. The primary end point of the study was the rate of death at 30 days. Results: Of the 980 patients registered in the JCS-Shock Registry, the data of 320 patients were included in this analysis, after exclusion of patients who had not received the two agents and patients meeting the exclusion criteria. Of the 320 patients, 98 had received norepinephrine (N group), 142 had received dopamine (D group), and 80 had received both agents (N+D group). The acute mortality rates were 26.5, 25.4 and 46.2% in the N, D and N+D groups, respectively (p = 0.003). In a stratified analysis according to the renal function (eGFR [median: 43] ≥43 [normal renal function] versus eGFR <43 [reduced renal function]) at the time of admission, the acute mortality rates in the patients of the N, D and N+D groups with normal renal function were 7.8, 21.1 and 41.2%, respectively (p = 0.001), being significantly lower in the N group. On the other hand, the acute mortality rates in the patients of the N, D and N+D groups with reduced renal function were 46.8, 29.6 and 50.0%, respectively (p = 0.049), being significantly lower in the D group. Conclusion: Although norepinephrine is recommended as the first-line treatment, a trend towards more frequent use of dopamine was found in Japan. In addition, norepinephrine appeared to contribute to a reduction of the acute mortality in patients with normal renal function, while dopamine appeared to contribute to a reduction of the acute mortality in patients with reduced renal function." @default.
• W2563842059 created "2017-01-06" @default.
• W2563842059 creator A5001421629 @default.
• W2563842059 creator A5024575314 @default.
• W2563842059 creator A5030479956 @default.
• W2563842059 creator A5037100296 @default.
• W2563842059 creator A5039413936 @default.
• W2563842059 creator A5054999797 @default.
• W2563842059 creator A5062022557 @default.
• W2563842059 creator A5065397000 @default.
• W2563842059 creator A5073774735 @default.
• W2563842059 creator A5082936913 @default.
• W2563842059 creator A5083136198 @default.
• W2563842059 date "2015-11-10" @default.
• W2563842059 modified "2023-09-22" @default.
• W2563842059 title "Abstract 13004: The Effect of Vasopressor Agents in the Treatment of Cardiovascular Shock" @default.
• W2563842059 doi "https://doi.org/10.1161/circ.132.suppl_3.13004" @default.
• W2563842059 hasPublicationYear "2015" @default.
• W2563842059 type Work @default.
• W2563842059 sameAs 2563842059 @default.
• W2563842059 citedByCount "1" @default.
• W2563842059 countsByYear W25638420592020 @default.
• W2563842059 crossrefType "journal-article" @default.
• W2563842059 hasAuthorship W2563842059A5001421629 @default.
• W2563842059 hasAuthorship W2563842059A5024575314 @default.
• W2563842059 hasAuthorship W2563842059A5030479956 @default.
• W2563842059 hasAuthorship W2563842059A5037100296 @default.
• W2563842059 hasAuthorship W2563842059A5039413936 @default.
• W2563842059 hasAuthorship W2563842059A5054999797 @default.
• W2563842059 hasAuthorship W2563842059A5062022557 @default.
• W2563842059 hasAuthorship W2563842059A5065397000 @default.
• W2563842059 hasAuthorship W2563842059A5073774735 @default.
• W2563842059 hasAuthorship W2563842059A5082936913 @default.
• W2563842059 hasAuthorship W2563842059A5083136198 @default.
• W2563842059 hasConcept C126322002 @default.
• W2563842059 hasConcept C159641895 @default.
• W2563842059 hasConcept C164705383 @default.
• W2563842059 hasConcept C2778514916 @default.
• W2563842059 hasConcept C2781300812 @default.
• W2563842059 hasConcept C42219234 @default.
• W2563842059 hasConcept C513476851 @default.
• W2563842059 hasConcept C71924100 @default.
• W2563842059 hasConceptScore W2563842059C126322002 @default.
• W2563842059 hasConceptScore W2563842059C159641895 @default.
• W2563842059 hasConceptScore W2563842059C164705383 @default.
• W2563842059 hasConceptScore W2563842059C2778514916 @default.
• W2563842059 hasConceptScore W2563842059C2781300812 @default.
• W2563842059 hasConceptScore W2563842059C42219234 @default.
• W2563842059 hasConceptScore W2563842059C513476851 @default.
• W2563842059 hasConceptScore W2563842059C71924100 @default.
• W2563842059 hasIssue "suppl_3" @default.
• W2563842059 hasLocation W25638420591 @default.
• W2563842059 hasOpenAccess W2563842059 @default.
• W2563842059 hasPrimaryLocation W25638420591 @default.
• W2563842059 hasRelatedWork W1501572346 @default.
• W2563842059 hasRelatedWork W2007920416 @default.
• W2563842059 hasRelatedWork W2024337135 @default.
• W2563842059 hasRelatedWork W2069345029 @default.
• W2563842059 hasRelatedWork W2089103608 @default.
• W2563842059 hasRelatedWork W2145202087 @default.
• W2563842059 hasRelatedWork W2262126354 @default.
• W2563842059 hasRelatedWork W2373064532 @default.
• W2563842059 hasRelatedWork W2415071191 @default.
• W2563842059 hasRelatedWork W3141103624 @default.
• W2563842059 hasVolume "132" @default.
• W2563842059 isParatext "false" @default.
• W2563842059 isRetracted "false" @default.
• W2563842059 magId "2563842059" @default.
• W2563842059 workType "article" @default.